
Quarterly report 2025-Q2
added 07-31-2025
Integra LifeSciences Holdings Corporation Cash Flow 2011-2026 | IART
Annual Cash Flow Integra LifeSciences Holdings Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
129 M | 140 M | 264 M | 312 M | 204 M | 231 M | 200 M | 115 M | 116 M | 105 M | 83.6 M | 53.3 M | 59.1 M | 104 M |
Depreciation & Amortization |
42.4 M | 40.9 M | 40.1 M | 39.4 M | 42.1 M | 109 M | 111 M | 88.9 M | 72.7 M | 58.9 M | 61.1 M | 47 M | 52.6 M | 50.2 M |
Accounts Payables |
82.5 M | 92.3 M | 102 M | 61.8 M | 54.6 M | 113 M | 76 M | 94 M | 29.1 M | 34.8 M | 34.1 M | 50.8 M | 36.7 M | 27.7 M |
Accounts Receivables |
272 M | 259 M | 263 M | 232 M | 226 M | 275 M | 266 M | 252 M | 148 M | 132 M | 132 M | 118 M | 115 M | 118 M |
Total Inventories |
429 M | 390 M | 325 M | 317 M | 310 M | 316 M | 280 M | 296 M | 217 M | 211 M | 237 M | 207 M | 172 M | 171 M |
All numbers in USD currency
Quarterly Cash Flow Integra LifeSciences Holdings Corporation
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -11.3 M | - | - | 15.8 M | - | - | 26.2 M | - | 179 M | - | 44.3 M | - | 243 M | - | 69.1 M | - | 124 M | 53.9 M | 20.8 M | - | 142 M | 78 M | 29.5 M | - | 157 M | 77.7 M | 41.5 M | - | 103 M | 57.8 M | 28.9 M | - | 110 M | 63.1 M | 25 M | - | 79.2 M | 59.6 M | 31.6 M | - | 58.7 M | 27.6 M | 11.3 M | - | 41.6 M | 10.8 M | 7.85 M | - | 62.5 M | 34.6 M | 32.3 M | - | 69.6 M | 45.8 M | 21.3 M |
Depreciation & Amortization |
3.75 M | 3.7 M | 3.76 M | 3.71 M | 10.1 M | 3.21 M | 3.03 M | 3.11 M | - | 3.14 M | 3.3 M | 3.89 M | - | 4.11 M | 4.2 M | 4.53 M | - | 8.34 M | 8.07 M | 29.2 M | - | 5.06 M | 54 M | 27.1 M | - | 83.1 M | 54 M | 27.1 M | - | 62.3 M | 41.3 M | 19.7 M | - | 54.4 M | 36.3 M | 18.3 M | - | 40.6 M | 24.4 M | 11.8 M | - | 34 M | 29.2 M | 14 M | - | 35.7 M | 24 M | 11.4 M | - | 39.1 M | 25.8 M | 12.6 M | - | 37.3 M | 24.5 M | 9.96 M |
Accounts Payables |
92.8 M | 91.3 M | 77.7 M | 107 M | 94.4 M | 93.6 M | 99.8 M | 113 M | 102 M | 80.7 M | - | 88.4 M | 61.8 M | 59.6 M | 65.5 M | 61.5 M | 54.6 M | 54.6 M | 54.6 M | 54.6 M | 113 M | 113 M | 113 M | 113 M | 76 M | 76 M | 76 M | 76 M | 94 M | 94 M | 94 M | 94 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 34.8 M | 34.8 M | 34.8 M | 34.8 M | 28.9 M | 28.9 M | 34.1 M | 34.1 M | 50.8 M | 50.8 M | 50.8 M | 50.8 M | 36.7 M | 36.7 M | 36.7 M | 36.7 M | 27.7 M | 27.7 M | 27.7 M | 27.7 M |
Accounts Receivables |
285 M | 252 M | 248 M | 271 M | 241 M | 256 M | 259 M | 254 M | 263 M | 248 M | - | 234 M | 232 M | 222 M | 230 M | 224 M | 226 M | 226 M | 226 M | 226 M | 275 M | 275 M | 275 M | 275 M | 266 M | 266 M | 266 M | 266 M | 252 M | 252 M | 252 M | 252 M | 148 M | 148 M | 148 M | 148 M | 132 M | 132 M | 132 M | 132 M | 110 M | 110 M | 132 M | 132 M | 118 M | 118 M | 118 M | 118 M | 115 M | 115 M | 115 M | 115 M | 118 M | 118 M | 118 M | 118 M |
Total Inventories |
465 M | 445 M | 437 M | 422 M | 403 M | 366 M | 354 M | 351 M | 325 M | 311 M | - | 328 M | 317 M | 327 M | 324 M | 328 M | 310 M | 310 M | 310 M | 310 M | 316 M | 316 M | 316 M | 316 M | 280 M | 280 M | 280 M | 280 M | 296 M | 296 M | 296 M | 296 M | 217 M | 217 M | 217 M | 217 M | 211 M | 211 M | 211 M | 211 M | 189 M | 189 M | 237 M | 237 M | 207 M | 207 M | 207 M | 207 M | 172 M | 172 M | 172 M | 172 M | 171 M | 171 M | 171 M | 171 M |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Integra LifeSciences Holdings Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical devices sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
$ 2.22 | 5.21 % | $ 3.47 M | ||
|
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
- | 3.58 % | $ 2.21 M | ||
|
AdaptHealth Corp.
AHCO
|
$ 10.45 | 0.29 % | $ 1.41 B | ||
|
Cognyte Software Ltd.
CGNT
|
$ 8.36 | -0.24 % | $ 600 M | ||
|
Alphatec Holdings
ATEC
|
$ 13.05 | 3.57 % | $ 1.96 B | ||
|
Avinger
AVGR
|
- | -20.74 % | $ 369 K | ||
|
Aziyo Biologics
AZYO
|
- | 1.37 % | $ 20.5 M | ||
|
Butterfly Network
BFLY
|
$ 4.27 | 9.21 % | $ 904 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Boston Scientific Corporation
BSX
|
$ 71.2 | 2.02 % | $ 105 B | ||
|
EDAP TMS S.A.
EDAP
|
$ 4.06 | 2.53 % | $ 151 M | ||
|
Apollo Endosurgery
APEN
|
- | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
$ 37.34 | -0.16 % | $ 1.16 B | ||
|
Cytosorbents Corporation
CTSO
|
$ 0.68 | 4.61 % | $ 37 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
ClearPoint Neuro
CLPT
|
$ 11.16 | 1.18 % | $ 302 M | ||
|
Dynatronics Corporation
DYNT
|
- | 14.99 % | $ 929 K | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Establishment Labs Holdings
ESTA
|
$ 65.01 | 2.41 % | $ 1.93 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
$ 18.45 | 0.16 % | $ 121 M | ||
|
InMode Ltd.
INMD
|
$ 13.65 | 1.64 % | $ 882 M | ||
|
GBS
GBS
|
- | -0.57 % | $ 7.12 M | ||
|
Abbott Laboratories
ABT
|
$ 110.71 | 0.69 % | $ 193 B | ||
|
Delcath Systems
DCTH
|
$ 9.74 | -0.71 % | $ 349 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 2.6 | 0.39 % | $ 153 M | ||
|
Bio-Rad Laboratories
BIO
|
$ 269.48 | 3.15 % | $ 7.6 B | ||
|
Helius Medical Technologies
HSDT
|
$ 2.17 | -0.91 % | $ 1.32 M | ||
|
AxoGen
AXGN
|
$ 32.75 | -0.27 % | $ 1.51 B | ||
|
Align Technology
ALGN
|
$ 176.12 | 3.94 % | $ 13.2 B | ||
|
Bruker Corporation
BRKR
|
$ 33.74 | 2.99 % | $ 5.03 K | ||
|
BioSig Technologies
BSGM
|
- | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
$ 3.74 | 1.91 % | $ 154 M | ||
|
Second Sight Medical Products
EYES
|
- | -0.97 % | $ 54.4 M | ||
|
Accuray Incorporated
ARAY
|
$ 0.39 | -6.07 % | $ 40.1 M | ||
|
IRIDEX Corporation
IRIX
|
$ 1.33 | - | $ 21.5 M | ||
|
IRadimed Corporation
IRMD
|
$ 102.8 | 1.09 % | $ 1.31 B |